First Trust Nasdaq Pharmaceuticals ETFFTXH
FTXH
0
Funds holding %
of 6,812 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3.71% more ownership
Funds ownership: 39.73% [Q2] → 43.45% (+3.71%) [Q3]
7% less capital invested
Capital invested by funds: $8.12M [Q2] → $7.54M (-$582K) [Q3]
13% less funds holding
Funds holding: 24 [Q2] → 21 (-3) [Q3]
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
We haven’t received any recent analyst ratings for FTXH.
Financial journalist opinion
Positive
Zacks Investment Research
4 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Positive
Zacks Investment Research
7 months ago
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Positive
Zacks Investment Research
8 months ago
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
Neutral
Zacks Investment Research
10 months ago
A Look at Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Charts implemented using Lightweight Charts™